Related Experiment Video
Updated: Jul 5, 2026

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)
Published on: May 16, 2012
MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer
Oskar W Rokhlin1, Vladimir S Scheinker, Agshin F Taghiyev
1Department of Pathology, The University of Iowa, Iowa City, Iowa 52242, USA. oskar-rokhlin@uiowa.edu
Abstract:
We investigated whether knocking down AR expression effects apoptosis after treatment with different apoptosis-inducing agents. We found that siRNA AR (si-AR) significantly decreased apoptosis induced by topoisomerase inhibitors doxorubicin (DOX) and camptothecin (Campt). It is known that DNA double-strand break inducing agents leads to activation (phosphorylation) of p53 that in turn regulates the expression of a variety of apoptosis-related genes including microRNA(miR)-34a and 34b/c. We found that DOX induced five phosphorylation sites of p53 (Ser15, 20, 37, 46 and 392); all of these sites were inhibited by si-AR. Subsequently we identified three kinases, SPAK, MDC1 and CaMKII that are under AR control and two of them, MDC1 and CaMKII, apparently participate in p53 upstream events that resulted in p53 inhibition. Using qPCR we showed that the level of miR-34a increased by 3-fold after DOX, but no increase was found with si-AR. MiR-34c expression increased 27 fold after DOX and only by 2.7 times with si-AR. It appears that AR-dependent inhibition of p53 resulted in suppression of miR-34a and -34c expression. Importantly, DOX did not induce miR-34 in LNCaP grown in an androgen free medium or in AR-negative prostate cancer cell lines, DU145 and PC3. To directly investigate the role of miR-34 in DOX-mediated apoptosis, we transfected cells with anti-miR-34 oligonucleotides or with miR-34. We found that inhibition of individual miR-34, either 34a or 34c, or forced overexpression of miR-34a or miR-34c did not modulate DOX-mediated apoptosis. Only simultaneous inhibition or forced overexpression of both miR-34 resulted in modulation of DOX-mediated apoptosis. Taken together, our data indicate that cooperation between miR-34a and 34c plays an important role in AR-dependent p53-mediated apoptosis in prostate cancer.
Insights
Knocking down androgen receptor (AR) reduces apoptosis in prostate cancer cells treated with chemotherapy. AR inhibition blocks p53 activation and suppresses miR-34a/34c expression, impacting cell death pathways.
Area of Science:
- Molecular Biology
- Oncology
- Cellular Biology
Background:
- Androgen receptor (AR) plays a critical role in prostate cancer progression.
- Apoptosis induction is a key mechanism for cancer therapy.
- The interplay between AR, p53, and microRNAs in apoptosis is not fully elucidated.
Purpose of the Study:
- To investigate the effect of AR knockdown on apoptosis induced by chemotherapeutic agents.
- To elucidate the role of AR in the p53 and microRNA-34 signaling pathway in prostate cancer cells.
Main Methods:
- RNA interference (siRNA) to knock down AR expression.
- Treatment with topoisomerase inhibitors (doxorubicin, camptothecin).
- Western blotting for p53 phosphorylation, quantitative PCR (qPCR) for microRNA expression, and apoptosis assays.
- Transfection with anti-miRNA oligonucleotides and miRNA mimics.
Main Results:
- AR knockdown significantly decreased doxorubicin- and camptothecin-induced apoptosis.
- AR knockdown inhibited p53 phosphorylation at multiple sites and suppressed miR-34a and miR-34c expression.
- Cooperative function of miR-34a and miR-34c was necessary for modulating doxorubicin-mediated apoptosis.
Conclusions:
- AR signaling is essential for p53-mediated apoptosis in response to DNA-damaging agents in prostate cancer.
- AR regulates p53 activation and subsequent miR-34a/34c expression, contributing to chemoresistance.
- Targeting AR or the cooperative function of miR-34a/34c may represent a therapeutic strategy for prostate cancer.
Related Concept Videos
Abnormal Proliferation
MicroRNAs
MicroRNAs
Negative Regulator Molecules
The Intrinsic Apoptotic Pathway
Experimental RNAi

